Vistagen , a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of ...
Details: Randomized, double-blind, placebo-controlled trial involving 338 outpatients with MDD, conducted over an 8-week monotherapy period (250mg BID). Initial results from the OLIVE trial are ...
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in ...